Literature DB >> 11469980

Extraintestinal Complications of Inflammatory Bowel Disease.

Ad A. van Bodegraven1, Ben A. C. Dijkmans, Paul Lips, Tom J. Stoof, A. Salvador Peña, Stephan G. M. Meuwissen.   

Abstract

Extraintestinal complications of inflammatory bowel disease (IBD) are often secondary to the underlying disease. Therefore, the first priority is to get active IBD into remission with medications, since surgery for IBD is not indicated for the treatment of extraintestinal complications. Symptoms of extraintestinal complications usually can be treated with simple agents; the treatment of patients with refractory symptoms and the use of more complex drug regimens should be done in cooperation with specialists on affected organ systems. Careful consideration of prescribed drugs is necessary because they may negatively influence the course of IBD.

Entities:  

Year:  2001        PMID: 11469980     DOI: 10.1007/s11938-001-0035-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  88 in total

Review 1.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

4.  Novel and selective calcitonin-inducing agents.

Authors:  A M Gilbert; S Caltabiano; D Roberts; S F Sum; G D Francisco; K Lim; M Asselin; J W Ellingboe; Y Kharode; A Cannistraci; R Francis; M TrailSmith; D Gralnick
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 7.446

Review 5.  Thromboembolism in inflammatory bowel disease.

Authors:  M Schapira; J Henrion; C Ravoet; J M Maisin; J M Ghilain; S De Maeght; F Heller
Journal:  Acta Gastroenterol Belg       Date:  1999 Apr-Jun       Impact factor: 1.316

Review 6.  The sacroiliac joint in the spondyloarthropathies.

Authors:  J Braun; J Sieper
Journal:  Curr Opin Rheumatol       Date:  1996-07       Impact factor: 5.006

7.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 8.  Prevention of osteoporotic fractures in post-menopausal women.

Authors:  J Compston
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  2000-06

9.  Therapy of rheumatoid arthritis with mycophenolate mofetil.

Authors:  R Goldblum
Journal:  Clin Exp Rheumatol       Date:  1993 Mar-Apr       Impact factor: 4.473

10.  Treatment of pyoderma gangrenosum with cyclosporine.

Authors:  W L Matis; C N Ellis; C E Griffiths; G S Lazarus
Journal:  Arch Dermatol       Date:  1992-08
View more
  1 in total

1.  Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Adrian A. Van Bodegraven; A. Salvador Peña
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.